339 related articles for article (PubMed ID: 18292976)
1. Cost-effective osteoporosis treatment thresholds: the United States perspective.
Tosteson AN; Melton LJ; Dawson-Hughes B; Baim S; Favus MJ; Khosla S; Lindsay RL;
Osteoporos Int; 2008 Apr; 19(4):437-47. PubMed ID: 18292976
[TBL] [Abstract][Full Text] [Related]
2. Cost-effective osteoporosis treatment thresholds in Greece.
Makras P; Athanasakis K; Boubouchairopoulou N; Rizou S; Anastasilakis AD; Kyriopoulos J; Lyritis GP
Osteoporos Int; 2015 Jul; 26(7):1949-57. PubMed ID: 25740208
[TBL] [Abstract][Full Text] [Related]
3. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
Ni W; Jiang Y
Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
[TBL] [Abstract][Full Text] [Related]
4. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.
Dawson-Hughes B; Tosteson AN; Melton LJ; Baim S; Favus MJ; Khosla S; Lindsay RL;
Osteoporos Int; 2008 Apr; 19(4):449-58. PubMed ID: 18292975
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
[TBL] [Abstract][Full Text] [Related]
6. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.
Borgström F; Johnell O; Kanis JA; Jönsson B; Rehnberg C
Osteoporos Int; 2006 Oct; 17(10):1459-71. PubMed ID: 16847588
[TBL] [Abstract][Full Text] [Related]
7. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
Pike C; Birnbaum HG; Schiller M; Sharma H; Burge R; Edgell ET
Pharmacoeconomics; 2010; 28(5):395-409. PubMed ID: 20402541
[TBL] [Abstract][Full Text] [Related]
8. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
9. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.
Burge R; Dawson-Hughes B; Solomon DH; Wong JB; King A; Tosteson A
J Bone Miner Res; 2007 Mar; 22(3):465-75. PubMed ID: 17144789
[TBL] [Abstract][Full Text] [Related]
10. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.
Kanis JA; Johnell O; Oden A; Borgstrom F; Johansson H; De Laet C; Jönsson B
Osteoporos Int; 2005 Jan; 16(1):6-14. PubMed ID: 15103452
[TBL] [Abstract][Full Text] [Related]
11. Intervention thresholds for osteoporosis.
Kanis JA; Johnell O; Oden A; De Laet C; Oglesby A; Jönsson B
Bone; 2002 Jul; 31(1):26-31. PubMed ID: 12110408
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls.
Ito K
JAMA Netw Open; 2020 Dec; 3(12):e2027584. PubMed ID: 33258906
[TBL] [Abstract][Full Text] [Related]
13. The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system.
Solomon DH; Patrick AR; Schousboe J; Losina E
J Bone Miner Res; 2014 Jul; 29(7):1667-74. PubMed ID: 24443384
[TBL] [Abstract][Full Text] [Related]
14. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture.
Majumdar SR; Lier DA; Rowe BH; Russell AS; McAlister FA; Maksymowych WP; Hanley DA; Morrish DW; Johnson JA
Osteoporos Int; 2011 Jun; 22(6):1799-808. PubMed ID: 20878389
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
17. Cost-effective osteoporosis treatment thresholds for people living with HIV infection in Greece.
Makras P; Boubouchairopoulou N; Katsarolis I; Athanasakis K
J Musculoskelet Neuronal Interact; 2017 Dec; 17(4):292-298. PubMed ID: 29199188
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
Johnell O; Jönsson B; Jönsson L; Black D
Pharmacoeconomics; 2003; 21(5):305-14. PubMed ID: 12627984
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
